Full Breakdown
Bipartisan Lawmakers Challenge CMS Fixed-Dose Combination Proposal
By Drooid · · How we work
Core Opposition to the Proposed Rule
A coalition of over 50 members of Congress from both parties has urged the Centers for Medicare & Medicaid Services (CMS) to withdraw a draft rule that would subject fixed-dose combination drugs to Medicare price negotiations immediately after Food and Drug Administration (FDA) approval. The lawmakers argue the policy could deter pharmaceutical companies from developing improved cancer therapies and other advanced treatments.
Background: Medicare Drug Price Negotiation Program
The Medicare Drug Price Negotiation Program was established under the Inflation Reduction Act, signed into law in 2022. The Trump administration introduced the fixed-dose combination provision in June as part of its effort to implement the program. The rule aims to prevent manufacturers from avoiding negotiated prices by making only minor modifications to existing drugs and marketing them as new products.
Lawmakers’ Concerns and Key Figures
The letter, signed by representatives including John Joyce (R-PA), Darin LaHood (R-IL), Mike Kennedy (R-UT), Tim Moore (R-NC), Jim Costa (D-CA) and Donald Davis (D-NC), contends that the proposal would force newer versions of drugs—such as cancer immunotherapies that allow quicker injections—to enter price negotiations prematurely. They note that the FDA already treats these therapies as distinct medicines, requiring separate clinical trials and approvals, and argue that CMS actuaries have not demonstrated meaningful taxpayer savings from the rule.
CMS Response
CMS Administrator Dr. Mehmet Oz has defended the proposal, stating it is intended to stop drugmakers from sidestepping negotiated Medicare prices by making only limited changes to existing products. The agency has not provided a comment to Fox News Digital at the time of reporting.
Potential Impact on Patient Access
If finalized, the rule could limit patient access to the latest cancer treatments, particularly in rural areas where faster, injectable therapies are valued. Lawmakers assert that restricting these advances would undermine incentives for innovation and reduce the availability of lifesaving care for patients battling serious diseases.